Review
Copyright ©The Author(s) 2020.
World J Hepatol. Aug 27, 2020; 12(8): 423-435
Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.423
Table 1 Potential pathways as targets for existing antibodies
DrugPrimary role of the pathway in specific cholestatic liver diseasePrevious disease of drug-testingRef.
Anti-CD40 (dacetuzumab/lucatumumab)T-cell-B-cell interactions in primary biliary cholangitisMultiple sclerosis (pre-clinical)[53]
Anti-CXCL10 (MDX-1100)CXCR3-CXCL9/10/11 CXCR3 is upregulated on liver-infiltrating Th1 and Th17 in primary biliargy cholangitisRheumatoid arthritis[54]
Anti-CXCL13 (Mab 5261)T- and B-cell migration to germinal centers in primary biliary cholangitisPreclinical development[55]
Anti-CCR6Recruitment of Th17 cells around inflamed biliary epithelial cells in primary biliary cholangitisPreclinical development[56]
Anti-GRP35Activation of GPR35 reduces IL-4 release from natural killer T cells in primary sclerosing cholangitisAntibody recently developed[57]
Anti-PRKD2SIK2 pathway in PSC, AMPK-related kinase PRKD2 polymorphism are seen in early inflammatory bowel disease in primary sclerosing cholangitisPreclinical development[58]